AOD-9604 vs HGH Fragment 176-191
Written by the Pure Peptides editorial team
Reviewed by Dr. Martina Rossi, PhD
Scientific Contributor and Reviewer · Reviewed
Published · Updated · 12 references
AOD-9604 and HGH Fragment 176-191 are different molecules: both are 16-residue peptides from the C-terminal end of human growth hormone, and AOD-9604 carries a tyrosine in place of phenylalanine at position 176.
Structure at a glance
AOD-9604
HGH Fragment 176-191
Letters are one-letter amino acid codes.
Drawn from the product database. Each measure's bars share one scale.
| Property | AOD-9604 | HGH Fragment 176-191 |
|---|---|---|
| What it is | A 16-residue peptide: residues 177 to 191 at the C-terminal end of human growth hormone, with a tyrosine in place of the phenylalanine at position 176.[1] | A 16-residue peptide: residues 176 to 191 at the C-terminal end of human growth hormone. |
| How they relate | Two molecules derived from the same parent, human growth hormone. Their formulas differ by one oxygen atom, the difference between tyrosine and phenylalanine. | |
| CAS number | 221231-10-3 | 66004-57-7 |
| Molecular formula | C78H123N23O23S2 | C78H123N23O22S2 |
| Molecular weight | 1,815.10 g/mol | 1,799.10 g/mol |
| Sequence | YLRIVQCRSVEGSCGF | FLRIVQCRSVEGSCGF |
| Target | A 2026 rodent study by developer-linked authors reported LanCL1 as a binding target.[11] FDA called it unknown in 2024.[2] | No target established for HGH Fragment 176-191. None reported; an absence in the record, not a demonstrated absence in biology. |
| Evidence base | Human trials: six randomized trials in about 900 adults; the one peer-reviewed report covers safety only.[3] The pivotal trial, in one indication, missed its primary endpoint.[2] Three later placebo-controlled trials, in other indications, found no significant effect.[10] | No published study has tested HGH Fragment 176-191 in people. In the literature reviewed for it, the fat-metabolism studies used AOD-9604 or a separate peptide, growth hormone residues 177 to 191. A 1978 study in normal rats did test synthetic 176-191 itself: it briefly raised blood glucose and raised plasma insulin.[12] |
| Regulatory status | No United States or European drug approval.[4] FDA states that neither its free base nor its acetate is a component of an approved drug.[4] | No marketing authorization, and no FDA approval for human use. |
| Compared head-to-head? | No direct comparison found in PubMed (searched October 2026).[5] | |
| Handling difference | Both formulas carry two sulfur atoms, enough to form one disulfide bridge, which a reducing agent opens. | |
| Where they get confused | A 2026 review gives hGH 176-191 as another name for AOD-9604, so the merge of the two names has reached the peer-reviewed literature.[6] Two papers in the literature reviewed for AOD-9604 studied a separate peptide, growth hormone residues 177 to 191 without the tyrosine, rather than AOD-9604. | |
How AOD-9604 and HGH Fragment 176-191 differ
AOD-9604 and HGH Fragment 176-191 are not the same molecule. Both are 16-residue peptides from the C-terminal end of human growth hormone. HGH Fragment 176-191 corresponds to residues 176 to 191 of the hormone, so it keeps the hormone's own phenylalanine at position 176. AOD-9604 corresponds to residues 177 to 191, with a tyrosine at its N-terminus in place of that phenylalanine.[1] Tyrosine is phenylalanine carrying an extra hydroxyl group, so the two formulas differ by one oxygen atom. Each compound has its own PubChem record. A 2026 review nonetheless gives hGH 176-191 as another name for AOD-9604, so the merge of the two names has reached the peer-reviewed literature.[6]
In the research program behind AOD-9604, clinical development was carried out with AOD-9604, not with HGH Fragment 176-191. No published study has tested HGH Fragment 176-191 in people. In the literature reviewed for HGH Fragment 176-191, the fat-metabolism studies used AOD-9604 or a separate peptide from the same program, growth hormone residues 177 to 191 without the tyrosine. Findings produced with either of those are not findings about HGH Fragment 176-191. A 1978 study in normal rats did test synthetic 176-191 itself: it briefly raised blood glucose and raised plasma insulin.[12] The literature reviewed for HGH Fragment 176-191 reports no human safety data. In the literature reviewed for AOD-9604, the rodent work came from the laboratory that originated the compound, and independent replication is essentially absent.[7][8][9] Two papers in that literature studied the separate peptide rather than AOD-9604, in animal or in vitro work.
In people, AOD-9604 was tested in six randomized trials in about 900 adults; the one peer-reviewed report of their pooled data covers safety only.[3] The compound's developer funded both safety papers, that report among them, and its chief executive, who held a stake in the parent company, co-authored them.[3] In a 2024 briefing document, FDA reported that the pivotal trial, in one indication, missed its primary endpoint, and that its developer terminated development in that indication in 2007.[2] Three later randomized placebo-controlled trials of the same peptide, in other indications, found no significant difference from placebo on their primary measures.[10] In a separate AOD-9604 trial in 300 adults, four cancers and one benign lipoma occurred, all in active arms and none on placebo.[3]
Have AOD-9604 and HGH Fragment 176-191 been compared directly?
No direct comparison of AOD-9604 and HGH Fragment 176-191 was found in a PubMed search run in October 2026.[5] That search covers PubMed only.
Read more on each compound
AOD-9604
Frequently Asked Questions
Is AOD-9604 the same as HGH Fragment 176-191?+−
AOD-9604 is not the same molecule as HGH Fragment 176-191, though both are 16-residue peptides from the C-terminal end of human growth hormone. AOD-9604 carries a tyrosine in place of the phenylalanine at position 176. Their formulas differ by one oxygen atom, and each compound has its own PubChem record.
Does research on AOD-9604 apply to HGH Fragment 176-191?+−
Findings produced with AOD-9604, or with a separate peptide from the same research program, are not findings about HGH Fragment 176-191. No published study has tested HGH Fragment 176-191 in people. Its reviewed fat-metabolism studies used AOD-9604 or that separate peptide. A 1978 rat study of 176-191 itself examined blood glucose and insulin.
References
- 1Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. 2015. PMID 25208511. DOI: 10.1002/dta.1715.
- 2US Food and Drug Administration. Briefing Document, Pharmacy Compounding Advisory Committee meeting, 4 December 2024 (memo dated 5 November 2024), including its Nonclinical Assessment section. Underlying disclosure by the compound's developer, 21 February 2007, SEC-filed. No PMID or DOI. fda.gov
- 3Pooled safety report, 2013. DOI: 10.4021/jem157w. Not indexed in PubMed; no PMID, so the DOI was resolved on Crossref on 28 August 2026 and the title and author line confirmed there. The only peer-reviewed publication reporting primary pooled data from the AOD-9604 human program; it reports safety only. doi.org
- 4openFDA drug/label and drug/drugsfda endpoints, field-qualified on openfda.substance_name, openfda.generic_name and openfda.brand_name, queried 27 August 2026, with control queries confirming the fields are populated; EMA European Public Assessment Report dataset, same date; FDA Briefing Document 4 December 2024, p. 7; the developer's ASX announcement, 26 April 2013.
- 5
PubMed search, 3 October 2026 (records to 2 October 2026)
2 records; none was a direct comparison of the two compounds.
Exact query (NCBI E-utilities): ("AOD-9604"[tiab] OR "AOD9604"[tiab] OR "AOD 9604"[tiab] OR "Tyr-hGH"[tiab]) AND ("176-191"[tiab] OR "fragment 176-191"[tiab] OR "frag 176-191"[tiab] OR "hGH fragment"[tiab] OR "hGH 176-191"[tiab] OR "somatotropin (176-191)"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])
View this search on PubMed - 6Dominikowski A, et al. Frontiers in Endocrinology. 2026. PMID 42395176. DOI: 10.3389/fendo.2026.1822475.
- 10ClinicalTrials.gov records NCT03865953, NCT04153409 and NCT05298306, read 16 October 2026: three completed randomized, double-blind, placebo-controlled crossover trials of the same peptide under a later development code, each with results posted and none significant on its primary measure. The EU Clinical Trials Register, EudraCT 2018-004534-15, records that code as previously AOD9604.
- 11Spanswick DC, Wei H, Zhao FY, et al. Pain. 2026;167(8):1850-68. doi:10.1097/j.pain.0000000000004014. PMID 42263267. Rodent study; authors include the developer's staff and advisers.

Reviewed for scientific accuracy
Dr. Martina Rossi, PhD
PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer
Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.
Related comparisons
AOD-9604 vs Tesamorelin
AOD-9604 is a modified 16-residue peptide from the C-terminal end of human growth hormone; Tesamorelin is a 44-residue analog of human GHRH.
Read ComparisonHGH Fragment 176-191 vs Tesamorelin
HGH Fragment 176-191 is a 16-residue fragment of human growth hormone; Tesamorelin is a 44-residue analog of human GHRH.
Read ComparisonCJC-1295 (No DAC) vs CJC-1295 with DAC
CJC-1295 with DAC is a chemically modified form of CJC-1295 (No DAC); the DAC-free peptide is essentially uncharacterized in humans.
Read Comparison

